. .. Discussion, 37 3. Les freins à l'optimisation du traitement de l'insuffisance cardiaque en médecine générale

. .. Limites,

C. .. ,

B. .. ,

. .. Liste-des-tableaux,

L. .. Serment-medical,

A. .. ,

R. .. ,

C. De-peretti, C. Pérel, P. Tuppin, M. C. Iliou, Y. Juillière et al., Prévalences et statut fonctionnel des cardiopathies ischémiques et de l'insuffisance cardiaque dans la population adulte en France: apports des enquêtes déclaratives «Handicap-Santé», Bull Epidémiol Hebd, vol.9, pp.172-181, 2014.

G. S. Bleumink, A. M. Knetsch, M. C. Sturkenboom, S. M. Straus, A. Hofman et al., Quantifying the heart failure epidemic: prevalence, incidence rate, lifetime risk and prognosis of heart failure: the Rotterdam Study, Eur Heart J, vol.25, issue.18, pp.1614-1619, 2004.

D. and S. France, L'état de santé de la population en France, pp.250-253, 2017.

C. De-peretti, Mortalité après hospitalisation pour motif cardio-vasculaire. Direction de la Recherche, de Etudes, de l'Evaluation, des Statistiques, vol.21, 2017.

S. Stewart, K. Macintyre, D. J. Hole, S. Capewell, and J. J. Mcmurray, More 'malignant'than cancer? Five-year survival following a first admission for heart failure, Eur J Heart Fail, vol.3, issue.3, pp.315-322, 2001.

S. Setoguchi, L. W. Stevenson, and S. Schneeweiss, Repeated hospitalizations predict mortality in the community population with heart failure, Am Heart J, vol.154, issue.2, pp.260-266, 2007.

M. Franzin-garrec and . L'insuffisance-cardiaque, Une maladie chronique en augmentation alarmante, Soins. avr, vol.58, issue.774, p.25, 2013.

, Caisse Nationale d'Assurance Maladie. Caractéristiques et trajets de soins des insuffisants cardiaques du régime général. Points de repère, revue de l'assurance maladie n°38, août, issue.38, 2012.

, Participation à la conférence de presse du Groupe Insuffisance Cardiaque et Cardiomyopathies-2

S. , , p.16, 2017.

. Disponible,

P. Ponikowski and A. , ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC), Eur Heart J, vol.37, issue.27, pp.1765-1773, 1994.

, Effects of enalapril on mortality in severe congestive heart failure, N Engl J Med, vol.316, issue.23, pp.1429-1435, 1987.

*. Investigators, Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure, N Engl J Med, vol.325, issue.5, pp.293-302, 1991.

J. B. Young, M. E. Dunlap, M. A. Pfeffer, J. L. Probstfield, A. Cohen-solal et al., Mortality and morbidity reduction with Candesartan in patients with chronic heart failure and left ventricular systolic dysfunction: results of the CHARM low-left ventricular ejection fraction trials, Circulation, vol.110, issue.17, pp.2618-2626, 2004.

B. Pitt, F. Zannad, W. J. Remme, R. Cody, A. Castaigne et al., The effect of spironolactone on morbidity and mortality in patients with severe heart failure, N Engl J Med, vol.341, issue.10, pp.709-717, 1999.

F. Zannad, J. J. Mcmurray, H. Krum, D. J. Van-veldhuisen, K. Swedberg et al.,

, Eplerenone in patients with systolic heart failure and mild symptoms, N Engl J Med, vol.364, issue.1, pp.11-21, 2011.

J. J. Mcmurray, M. Packer, A. S. Desai, J. Gong, M. P. Lefkowitz et al.,

, Angiotensin-neprilysin inhibition versus enalapril in heart failure, N Engl J Med, vol.371, issue.11, pp.993-1004, 2014.

G. and L. Lettre,

. Disponible, J. N. Trochu, S. Baleynaud, G. Mialet, C. Thomas et al.,

M. S. Nieminen, D. Brutsaert, K. Dickstein, H. Drexler, F. Follath et al., Multicentre randomised trial of a multidisciplinary intervention program in heart failure patients in French medical practice, EUROPEAN HEART JOURNAL, vol.20, pp.484-484, 2003.

, EHFS II): a survey on hospitalized acute heart failure patients: description of population, EuroHeart Failure Survey II, vol.27, issue.22, pp.2725-2736, 2006.

P. De-groote, R. Isnard, P. Assyag, P. Clerson, A. Ducardonnet et al., Is the gap between guidelines and clinical practice in heart failure treatment being filled? Insights from the IMPACT RECO survey, Eur J Heart Fail, vol.9, issue.12, pp.1205-1211, 2007.

G. Poelzl, J. Altenberger, R. Pacher, C. H. Ebner, M. Wieser et al., Dose matters! Optimisation of guideline adherence is associated with lower mortality in stable patients with chronic heart failure, Int J Cardiol, vol.175, issue.1, pp.83-89, 2014.

M. Komajda, S. D. Anker, M. R. Cowie, G. S. Filippatos, B. Mengelle et al., Physicians' adherence to guideline-recommended medications in heart failure with reduced ejection fraction: data from the QUALIFY global survey, Eur J Heart Fail, vol.18, issue.5, pp.514-522, 2016.

A. Cohen-solal, Management of heart failure by general practitioners in France. Results of the study IMPROVEMENT of heart failure (IMPROVEMENT-HF). Arch Mal Coeur Vaiss, vol.95, pp.11-15, 2002.

G. Jondeau, F. A. Allaert, and I. Leurs, Management of heart failure by French general practitioners in 2003, Arch Mal Coeur Vaiss, vol.97, issue.9, pp.833-839, 2004.

. Insee, La grille communale de densité, 2018.

, Observatoire des Territoires, p.10, 2017.

. Disponible,

K. Swedberg, M. Komajda, M. Böhm, J. S. Borer, I. Ford et al.,

, Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study, The Lancet, vol.376, issue.9744, pp.875-885, 2010.

A. Sm, F. F. Gentile, K. K. Birtcher, A. S. Gidding, F. B. Bozkurt et al.,

A. , HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure

A. C. Solal, I. Leurs, P. Assyag, F. Beauvais, P. Clerson et al., Optimization of heart FailUre medical Treatment after hospital discharge according to left ventricUlaR Ejection fraction: the FUTURE survey, Arch Cardiovasc Dis, vol.105, issue.6-7, pp.355-365, 2012.

O. Miller, A. B. Blair, J. E. Konstam, M. A. Wedge, P. Bahit et al., Causes of death and rehospitalization in patients hospitalized with worsening heart failure and reduced left ventricular ejection fraction: results from Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan (EVEREST) program, Am Heart J, vol.159, issue.5, pp.841-849, 2010.

T. Pezel, Characteristics of heart failure patients using a Smartphone in the OFICSel cohort to develop a futur specific numeric application, 2018.

. Disponible,

S. J. Greene, J. Butler, N. M. Albert, A. D. Devore, P. P. Sharma et al., Medical therapy for heart failure with reduced ejection fraction: the CHAMP-HF registry, J Am Coll Cardiol, vol.72, issue.4, pp.351-366, 2018.

, GICC. plus d'un million de personnes atteintes d'insuffisance cardiaque en France

!. Parlons-en, , 2017.

B. Pitt, G. Williams, W. Remme, F. Martinez, J. Lopez-sendon et al., The EPHESUS trial: eplerenone in patients with heart failure due to systolic dysfunction complicating acute myocardial infarction, Cardiovasc Drugs Ther, vol.15, issue.1, pp.79-87, 2001.

E. Berthelot, J. C. Eicher, M. Salvat, M. F. Seronde, and P. De-groote, Medical Inertia in the Optimization of Heart Failure Treatment after Discharge and its Relationship to Outcome, Health Care Curr Rev, vol.6, issue.221, p.2, 2018.

M. Packer, M. R. Bristow, J. N. Cohn, W. S. Colucci, M. B. Fowler et al., The effect of carvedilol on morbidity and mortality in patients with chronic heart failure, N Engl J Med, vol.334, issue.21, pp.1349-1355, 1996.

V. Maurin and . L'unité-de-traitement-de-l, Université de Bordeaux; 2014. 39. l'assurance maladie, Société Française de Cardiologie. retour à domicile après hospitalisation. suivi en ville après décompensation cardiaque, 2013.

. Disponible,

F. Picard, P. Bordachar, D. Santos, and P. , Suivi à distance des patients en insuffisance cardiaque, Mt Cardio, vol.4, issue.2, pp.104-111, 2008.

G. Le-gicc-innove-dans-le-parcours-de-soin and . Le-transfert-de-compétence,

, Groupe Insuffisance Cardiaque et Cardiomyopathies (GICC)-Paris

. Disponible,